Defunct Company
Total Trials
17
As Lead Sponsor
13
As Collaborator
4
Total Enrollment
1,515
NCT00091585
Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.
Phase: Phase 1
Role: Lead Sponsor
Start: Jun 30, 2004
Completion: Nov 30, 2006
NCT00094159
Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors
Start: Oct 31, 2004
Completion: Not specified
NCT00246662
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
Start: Nov 14, 2005
Completion: Apr 30, 2009
NCT00252382
Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC
Phase: Phase 2
Start: Dec 27, 2005
Completion: Nov 29, 2007
NCT00292864
Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors
Start: Jan 31, 2006
Completion: Dec 31, 2007
NCT00298896
Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
Start: Feb 28, 2006
Completion: Jun 30, 2008
NCT00408603
Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
Start: Dec 20, 2006
Completion: Jun 9, 2010
NCT00446342
Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
Start: Feb 28, 2007
Completion: Mar 31, 2009
NCT00519662
Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors
Start: Aug 31, 2007
NCT00541866
Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans
Phase: Phase 1/2
Start: Oct 6, 2007
Completion: Feb 15, 2012
NCT00607997
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
Start: May 15, 2008
Completion: Nov 23, 2009
NCT01191801
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML
Phase: Phase 3
Start: Dec 17, 2010
Completion: Mar 1, 2017
NCT01893320
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Role: Collaborator
Start: Jul 18, 2013
Completion: Jan 11, 2021
NCT01980056
Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy
Start: Oct 25, 2013
Completion: Jan 19, 2015
NCT01913951
Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
Start: Nov 22, 2013
Completion: Apr 29, 2024
NCT03037645
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
Start: Apr 28, 2017
Completion: Aug 31, 2020
NCT03338348
Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
Start: Apr 19, 2018
Completion: Oct 31, 2019